Loading patent…
AssigneeG.D. Searle & Co.
InventorsSusan L Hockerman, Daniel P. Becker, Louis J Bedell, Gary A DeCrescenzo, John N Freskos, Daniel P Getman, Robert M Heintz, Madeleine H Li, Brent V Mischke, Clara I Villamil, Thomas E Barta
Estimating the term…
A family of molecules is disclosed that inhibit matrix metalloprotease (MMP) activity, and particularly inhibit the activity of one or more of MMP-2, MMP-9, or MMP-13, while generally exhibiting little activity against MMP-1. A contemplated compound also exhibits little inhibition of the production of TNF. A contemplated compound is an α-amino-β-sulfonyl carbocyclo, heterocyclo, aryl, or heteroaryl hydroxamic acid. Also disclosed are processes for preparing a contemplated compound and for treating a mammal having a condition associated with pathological matrix metalloprotease activity.
A compound or pharmaceutically acceptable salt thereof, the compound corresponding in structure to a formula selected from the group consisting of:
A compound or pharmaceutically acceptable salt thereof, the compound corresponding in structure to a formula selected from the group consisting of:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, wherein said compound corresponds in structure to the formula below:
A compound or pharmaceutically acceptable salt thereof, the compound corresponding in structure to a formula selected from the group consisting of:
A compound corresponding in structure to a formula selected from the group consisting of:
A compound or a pharmaceutically acceptable salt thereof, wherein the compound corresponds in structure to the formula below:
Dependencies are inferred from the claim text.